戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d with the Abbott RealTime HIV-1 Qual assay (RealTime).
2 rocess that serves language comprehension in realtime.
3 ow latency for experimental interventions in realtime.
4  23-38]) of 150 participants based on Abbott RealTime.
5 ed the following Deming regression equation: RealTime = 0.940 (TaqMan) + 0.175 log(10) HCV RNA IU/ml.
6          However, using <12 IU/ml for Abbott RealTime, a similar proportion (74%) would be eligible.
7             In treated patients monitored by RealTime, a VL of 40-49 copies/mL and, to a lesser exten
8 patients with undetectable HCV RNA by Abbott RealTime achieved a sustained virologic response.
9 y this method to both interferogram and semi-realtime acquisition modes, obtaining integrals within 1
10                                              Realtime alerts of modified systemic inflammatory respon
11 onkeypox virus, 2 (MPXV+ and MPXV) for m2000 RealTime and 1 (MPXV) for Alinity m platforms.
12        Comparison of 216 samples analyzed by RealTime and TaqMan assays produced the following Deming
13 = 83.47 to 99.4%) between the results of the RealTime and TaqPath tests with 77 NP specimens (P = 0.2
14                               The LOD of the RealTime and two TaqMan assays was approximately 1.0 log
15                      We evaluated the Abbott RealTime (ART) and Roche Cobas TaqMan Hepatitis C virus
16  tracking of material degradation in vivo in realtime, as well as the formation of theranostic nanopa
17                           In conclusion, the RealTime assay accurately measured HCV viral loads over
18 rements for most samples and showed that the RealTime assay is able to detect all genotypes with no b
19 RNA as the cutoff, the more sensitive Abbott RealTime assay would identify fewer patients eligible fo
20 t, version 2.0, can act as a template in the RealTime assay, but potential cross-contamination could
21 y established in other studies of the Abbott RealTime assay, to determine eligibility for shortened P
22  SeraCare CMV DNA qualification panel to the RealTime assay.
23 opies/ml higher than those determined by the RealTime assay.
24 .072 log10copies/ml higher than those of the RealTime assay.
25 bbott investigational use only RealTime HCV (RealTime) assay using the Abbott m2000 platform and comp
26 NA loads in CVL samples, with the Aptima and RealTime assays detecting 30% and 20%, respectively.
27  samples were analyzed to compare Aptima and Realtime assays using Deming regression and Bland-Altman
28 NorChip), Aptima HPV (Gen-Probe), and Abbott RealTime assays, the BD HPV test, and CINtec p16(INK4a)
29 served for the two conditions tested for all RealTime assays.
30 2 (CAP/CTM) and Abbott m2000 RealTime HIV-1 (RealTime) assays on all subtype samples.
31                          For the qualitative RealTime C. trachomatis/N. gonorrhoeae assay, the overal
32 he test of record at each site (n = 304 with RealTime CMV and n = 153 with LDT CMV).
33 tion compared the Alinity m CMV assay to the RealTime CMV assay and a laboratory-developed test (LDT)
34 tima CMV Quant assay in comparison to Abbott RealTime CMV assay, Qiagen Artus CMV RGQ MDx assay, and
35  coefficient r >=0.942) in comparison to the RealTime CMV or LDT CMV assays.
36 CT/NG assay (GeneXpert) and the Abbott m2000 RealTime CT (m2000) assay were compared to Amplicor for
37  three separate screening assays, the Abbott RealTime CT/NG (Abbott Molecular, Inc., Des Plaines, IL)
38 racteristics of the newly FDA-cleared Abbott RealTime CT/NG assay (where "CT" stands for Chlamydia tr
39      In summary, we conclude that the Abbott RealTime CT/NG assay is an accurate and automated new ad
40                                   The Abbott RealTime CT/NG assay offers C. trachomatis and N. gonorr
41 ll sensitivity and specificity of the Abbott RealTime CT/NG assay were 92.4% and 99.2% for C. trachom
42 he performance characteristics of the Abbott RealTime CT/NG assay, a multiplex real-time PCR assay, f
43 cimens were tested with the automated Abbott RealTime CT/NG assay, Aptima Combo 2 assay (Gen-Probe),
44 omolecular imprinted polymer for label-free, realtime detection of N-hexanoyl-L-homoserine lactone (1
45  quantitative polymerase chain reaction, and realtime digital polymerase chain reaction).
46 to that after clinically validated cobas and RealTime DNA tests.
47  the Alinity m EBV assay was compared to the RealTime EBV assay and a laboratory-developed test (LDT)
48 the respective study sites (n = 148 with the RealTime EBV assay and n = 152 with the LDT EBV assay).
49                  Correlation with the Abbott Realtime EBV assay was assessed in clinical specimens an
50          Agreement between Alinity m EBV and RealTime EBV or LDT EBV assays had kappa values of 0.88
51 performed by RT-PCR on the Abbott SARS-CoV-2 RealTime emergency use authorization (EUA) (limit of det
52    This study was entirely open and received realtime feedback from 40 community members.
53 e performed rapidly and accurately using the realtime GeneSearch BLN Assay.
54                                       Abbott RealTime had 93.3% sensitivity, 27.3% specificity, and 3
55                                   The Abbott RealTime HBV assay targets the N-terminal region of the
56 s HBV DNA levels >15 IU/mL, using the Abbott RealTime HBV DNA assay.
57 BV) quantification were assessed: the Abbott RealTime HBV IUO, the Roche Cobas AmpliPrep/Cobas TaqMan
58 s AmpliPrep/CobasTaqMan (CAP/CTM) and Abbott RealTime HCV (ART) assays.
59 ation of the Abbott investigational use only RealTime HCV (RealTime) assay using the Abbott m2000 pla
60 s also similarly misquantified by the Abbott RealTime HCV assay.
61 Viral Load assay in comparison to the Abbott RealTime HCV assay.
62 e Roche COBAS TaqMan HCV test and the Abbott RealTime HCV assay.
63 ere compared to quantification by the Abbott RealTime HCV assay.
64                                   The Abbott RealTime HCV Genotype II RUO (research use only) assay w
65 che High Pure System/Cobas TaqMan and Abbott RealTime HCV RNA assays and the impacts of different HCV
66 those tested retrospectively with the Abbott RealTime HCV RNA test (ART).
67  and finger-stick collection with the Abbott RealTime HCV Viral Load assay (gold standard).
68 at the primer and probe binding sites of the RealTime HCV viral load assay are highly conserved and t
69 th simultaneous plasma results on the Abbott RealTime HIV-1 (Abbott Molecular, Des Plaines, IL) viral
70 (n = 25), Cobas TaqMan v2.0 (n = 11), Abbott RealTime HIV-1 (n = 23), Versant HIV-1 RNA bDNA 3.0 (n =
71  TaqMan HIV-1 v.2 (CAP/CTM) and Abbott m2000 RealTime HIV-1 (RealTime) assays on all subtype samples.
72 ir-resistant specimens were determined using RealTime HIV-1 and Roche Monitor (v1.5).
73 /Cobas TaqMan HIV-1 test (RT) and the Abbott RealTime HIV-1 assay (AR), that utilize real-time PCR ha
74 of HIV-1 viral load results using the Abbott RealTime HIV-1 assay and (ii) evaluate the effect of who
75 ant results were observed between the Abbott RealTime HIV-1 assay and the COBAS AmpliPrep/COBAS TaqMa
76 le in the two groups, demonstrating that the RealTime HIV-1 assay can tolerate raltegravir-selected m
77 Quant Dx assay in comparison with the Abbott RealTime HIV-1 assay using plasma and cervicovaginal lav
78 tly retested negative using the Abbott m2000 RealTime HIV-1 assay, which targets the integrase gene.
79 viral load results as measured by the Abbott RealTime HIV-1 assay.
80 te quantification of HIV-1 RNA in the Abbott RealTime HIV-1 assay.
81 sign strategy was demonstrated in the Abbott RealTime HIV-1 assay.
82 results from the Versant bDNA 3.0 and Abbott RealTime HIV-1 differed by greater than 0.5log10.
83 e specimens were also tested with the Abbott RealTime HIV-1 Qual assay (RealTime).
84 an (CAP/CTM) HIV-1 Qual test, and the Abbott RealTime HIV-1 Qualitative assay.
85 Amplicor Monitor, v1.5 (Monitor), the Abbott RealTime HIV-1 test on the m2000 system (Abbott), and th
86 Monitor v1.5 showed a tendency of the Abbott RealTime HIV-1 to under-estimate results while the TaqMa
87                                   The Abbott RealTime HIV-1 viral load assay uses primers and probes
88 re tested in pools of three using the Abbott RealTime HIV-1 Viral Load assay.
89 ntra and inter-assay variation of the Abbott RealTime HIV-1 were 2.95% (range 2.0-5.1%) and 5.44% (ra
90               Bias data comparing the Abbott RealTime HIV-1, TaqMan v2.0 to the Amplicor Monitor v1.5
91  the High Pure System or <12 IU/ml by Abbott RealTime; however, 92% of the patients with undetectable
92                                   The Abbott RealTime human immunodeficiency virus type 1 (HIV-1) ass
93 , including the ability to provide very fast realtime in situ analyses.
94                                              Realtime in situ temperature monitoring in difficult exp
95 High Pure System and reanalyzed using Abbott RealTime (limits of detection, 15.1 IU/ml versus 8.3 IU/
96 say was evaluated using the automated Abbott RealTime m2000 system.
97 y chi (omega, T), a general KWW form for the realtime magnetic relaxation, and a divergence of the mi
98 ay showed positive results for all DBS while RealTime missed five DBS with low target concentrations.
99                                              Realtime monitoring of neurotransmitters is of great int
100 mens in UTM were tested with RealTime MPXV+, RealTime MPXV and Alinity m MPXV assays and demonstrated
101                                        m2000 RealTime MPXV+ and MPXV assay sensitivity was determined
102                                        m2000 RealTime MPXV+ and MPXV assays were validated with lesio
103 cal lesion specimens in UTM were tested with RealTime MPXV+, RealTime MPXV and Alinity m MPXV assays
104                                              RealTime MPXV+, RealTime MPXV, and Alinity MPXV are high
105                              RealTime MPXV+, RealTime MPXV, and Alinity MPXV are high throughput and
106                                   The Abbott RealTime MTB assay is a nucleic acid amplification test
107  properties indicate a potential utility for realtime,multi-input processing of distributed sensory d
108                                              Realtime PCR (qPCR) was used to detect the expression of
109         A quantitative reverse-transcriptase RealTime PCR (qRT) assay was developed for these MAAs to
110                             Furthermore, our realtime PCR results were also found to be consistent wi
111 nd deconvolution microscopy and quantitative realtime PCR, we found that initiation and elongation oc
112  cytometry, multiplexing immunostaining, and realtime PCR.
113 luding OSX, DMP1, and Wnt3a, was observed by realtime PCR.
114  acid was genotyped for the rs4680 SNP using realtime polymerase chain reaction (PCR).
115 eptor (MET) were assessed using quantitative realtime polymerase chain reaction on a cohort of 64 liv
116 aft cytokine mRNA production was analyzed by realtime polymerase chain reaction on day 14 after trans
117                                          The realtime portion of the procedure demands minimal comput
118                                      We show realtime quantitative detection of a single-copy gene, K
119 qMan assay results were 100% concordant with RealTime results in EDTA plasma samples and in 100 HIV-1
120 sults fell within 0.5 log of the CAP/CTM and RealTime results, respectively.
121 strated results with >1-log differences from RealTime results.
122          We hypothesized that a quantitative realtime reverse transcriptase polymerase chain reaction
123 atory genes in early T-cell precursors using realtime RT-PCR.
124                                   The Abbott RealTime (RT) HCV assay targets the 5' untranslated regi
125  log(10) RNA IU/ml and was consistent across RealTime's dynamic range of nearly 7 log(10) HCV RNA IU/
126  = 97.97 to 100%) between the results of the RealTime SARS-CoV-2 and CDC tests with 217 NP specimens
127 ied the analytical performance of the Abbott RealTime SARS-CoV-2 assay on the m2000 system and compar
128 lso performed a bridging study comparing the RealTime SARS-CoV-2 assay with the new Abbott Alinity m
129 y m system due to the unread cycles with the RealTime SARS-CoV-2 assay.
130 cient of variation = 2.95%) using the Abbott RealTime SARS-CoV-2 Emergency Use Authorization (EUA) as
131 irst-time positive patients using the Abbott RealTime SARS-CoV-2 Emergency Use Authorization test.
132 2 commercial molecular amplification assays (RealTime SARS-CoV-2 on the m2000 [abbreviated ACOV; Abbo
133 st Device (nasal; Abbott) against the Abbott RealTime severe acute respiratory syndrome coronavirus 2
134 s AmpliPrep/Cobas TaqMan test and the Abbott RealTime test, are FDA cleared for use with EDTA plasma.
135 CAP/CTM values for subtypes F and G and than RealTime values for subtypes C, F, and G and CRF02_AG.
136  CAP/CTM values and 0.30 log higher than the RealTime values, and the values were >0.4 log higher tha
137 e for shorter treatment duration with Abbott RealTime versus 72% with the High Pure System.
138 dard condition results were observed for all RealTime viral load assays evaluated in this study, with
139                                              Realtime visual feedback from consequences of actions is
140 s approaches and highlight the potential for realtime VOC measurements to help overcome limitations i

 
Page Top